Polycystic kidney diseases (PKD) are inherited as autosomal dominant (ADPKD) or autosomal recessive (ARPKD) traits and are characterized by progressive enlargement of renal cysts. Aberrant cell proliferation is a key feature in the progression of PKD. Cux1 is a homeobox gene that is related to Drosophila cut and is the murine homolog of human CDP (CCAAT Displacement Protein). Cux1 represses the cyclin kinase inhibitors p21 and p27, and transgenic mice ectopically expressing Cux1 develop renal hyperplasia. However, Cux1 transgenic mice do not develop PKD. Here, we show that a 246 amino acid deletion in Cux1 accelerates PKD progression in cpk mice. Cystic kidneys isolated from 10-day-old cpk/Cux1 double mutant mice were significantly larger than kidneys from 10-day-old cpk mice. Moreover, renal function was significantly reduced in the Cux1 mutant cpk mice, compared with cpk mice. The mutant Cux1 protein was ectopically expressed in cyst-lining cells, where expression corresponded to increased cell proliferation and apoptosis, and a decrease in expression of the cyclin kinase inhibitors p27 and p21. While the mutant Cux1 protein altered PKD progression, kidneys from mice carrying the mutant Cux1 protein alone were phenotypically normal, suggesting the Cux1 mutation modifies PKD progression in cpk mice. During cell cycle progression, Cux1 is proteolytically processed by a nuclear isoform of the cysteine protease cathepsin-L. Analysis of the deleted sequences reveals that a cathepsin-L processing site in Cux1 is deleted. Moreover, nuclear cathepsin-L is significantly reduced in both human ADPKD cells and in Pkd1 null kidneys, corresponding to increased levels of Cux1 protein in the cystic cells and kidneys. These results suggest a mechanism in which reduced Cux1 processing by cathepsin-L results in the accumulation of Cux1, downregulation of p21/p27, and increased cell proliferation in PKD.
POLYCYSTIC KIDNEY DISEASE (PKD) is a term applied to a group of inherited disorders characterized by the presence of renal cysts; however, multiple organs are usually affected. Human autosomal dominant PKD (ADPKD) results from mutations in one of two genes, PKD1 or PKD2, that encode polycystin-1 and polycystin-2 proteins, respectively (39, 58 -60) . Human autosomal recessive PKD (ARPKD) results from mutations within a single gene, polycystic kidney and hepatic disease 1 (PKHD1), encoding fibrocystin/polyductin (47, 66) . Proteins that are mutated in human PKD (polycystin-1, polycystin-2, fibrocystin/polyductin), and in animal models of PKD (cystin, polaris), colocalize to the primary cilia (26, 46, 50, 69) . This suggests that mutations in ciliary proteins affect common or overlapping signaling pathways resulting in PKD (43) . The process of cyst formation in PKD is thought to involve various mechanisms including cell proliferation, fluid secretion, dedifferentiation, abnormal basement membrane formation, matrix remodeling, apoptosis, and alteration in cellular polarity (10, 19, 22, 27) . Growing evidence suggests that PKD is a developmental disorder (4, 7, 23, 26, 33, 34, 48, 67) .
The murine transcription factor Cux1 is structurally related to the Drosophila homeodomain protein cut and contains four putative DNA binding domains (3 cut repeats, 1 homeodomain) (1, 2, 44, 45, 51, 64, 70) . Drosophila cut is required for the proper development of the Malpighian tubules, the insect excretory and osmoregulatory organs (5, 6) . Cux1 represses the expression of the cyclin kinase inhibitor (CKI) p21 in S phase and is part of the network controlling G1-S transition (12) . Cux1 also represses the CKI p27, and ectopic expression of Cux1 in transgenic mice results in multiorgan hyperplasia from the aberrant downregulation of p27 (30) . In the kidney, Cux1 expression is spatially and temporally regulated, with highest expression in the nephrogenic zone, where it is associated with cell proliferation (30, 64) . During normal kidney development, p27 is absent from the nephrogenic zone, but is expressed in maturing glomeruli and tubules following the downregulation of Cux1 (11) . Thus, Cux1 is a cell cycle-dependent transcription factor that promotes cell proliferation during the early stages of nephrogenesis by repressing p27 gene expression.
In addition to the full-length isoform, called Cux1 (p200), there are several truncated isoforms. A nuclear isoform of the cysteine protease cathepsin-L has been identified that proteolytically processes Cux1 (p200) in S-phase (21) . While the full-length Cux1 protein (p200) contains three cut repeats and the homeodomain, the proteolytically processed Cux1 (p110 or p90) contains only cut repeats 2 and 3, together with the homeodomain (21) . Cux1 (p200) exhibits transient DNA binding activity and functions as a transcriptional repressor, whereas p110 stably binds DNA and can function as a transcriptional activator (40) . Other Cux1 isoforms result from alternate splicing (CASP) (31) , alternate promoter use (p75) (20) , or proteolytic processing (p150) (37) . Another Cux1 transcript, found exclusively in testis, encodes a 55-kDa protein; however, it is not known whether it originates by alternate splicing or an alternate promoter (65) .
Cux1 (p200) is highly expressed in cystic kidneys isolated from both Pkd1 null and cpk mice, murine models of ADPKD and ARPKD, respectively (53) . In cystic kidneys from Pkd1 null mice, Cux1 is highly expressed in both cyst-lining cells and in normal appearing tubule epithelium where expression of Cux1 is associated with increased cell proliferation. In cystic kidneys from cpk mice, Cux1 is not abnormally expressed until late stages of cystogenesis where expression of Cux1 is associated with increased apoptosis in cyst-lining cells. However, CMV/Cux1 transgenic mice do not develop cystic kidney disease. However, it was recently shown that transgenic mice ectopically expressing the p75 isoform of Cux1 develop renal abnormalities including renal tubule hyperplasia and cystic dilations with long latency (9) .
In the present study, we generated Cys1 cpk mice carrying a mutated allele of Cux1 to determine whether changes in Cux1 affect the progression of disease. The mutated Cux1 allele, called Cux1 tm1Ejn , carries an in-frame deletion of Cux1, encompassing exons 15 and 16 (63) . The Cux1 tm1Ejn mice display wavy hair and curly vibrissae, and females are unable to support pups because of lactation defects. However, the kidneys of these mice are phenotypically normal. The Cux1 tm1Ejn phenotype is similar to previously described mouse mutants in the EGFR pathway, including waved-1 (wa-1) (35, 38) and waved-2 (wa-2) (16, 36) . The role of EGFR in PKD has been well-described (18, 29, 32, 49, 54) . Moreover, blocking EGFR activity, either genetically using the wa-2 mutation, or pharmacologically, results in decreased cyst formation and improved kidney function (49, 55, 56 
MATERIALS AND METHODS

Animals. Cys1
cpk /ϩ and Cux1 tm1Ejn /J/ϩ mice were purchased from Jackson Laboratory (Bar Harbor, ME), and stock colonies are maintained at the University of Kansas Medical Center. The Cux1 tm1Ejn was generated by a targeted insertion of a construct to replace the first cut repeat introducing a nonsense mutation that would result in a truncated protein of ϳ60 kDa. However, the resulting mice expressed a mutant form of the protein with an internal deletion of 246 amino acids encompassing the first cut repeat domain, while the CR2, CR3, HD, and C-tail of Cux1 remained intact. The mRNA produced from the mutant mice allele was missing two exons, the exon encoding the first cut repeat and the subsequent exon. Identification of ϩ/ϩ, Cys1 cpk /ϩ, and Cys1 cpk genotypes was determined by PCR, as described (26) . The presence of the Cux1 tm1Ejn mutation was identified by Southern blot analysis, as described (63 Serum chemistry. Blood was collected by intracardiac puncture and immediately centrifuged at 2,000 g for serum collection. Blood urea nitrogen (BUN) was determined using an autoanalyzer (Physicians Reference Laboratory, LLC, Overland Park, KS).
Immunohistochemistry. Immunohistochemistry was performed as previously described (53) . Kidney sections were immersion fixed in Fig. 1 Western blot analysis. Human ADPKD and normal human kidney (NHK) were harvested and nuclear extracts were prepared as previously described (8, 18) . Nuclear extracts (45 g) were loaded onto 4 -15% SDS-PAGE gels and transferred to PVDF membranes where they were blocked in 5% milk PBST. Membranes were probed with Cux1 (1:50), Cathepsin-L (1:2,000), p27 (1:100), or p21 (1:100; Santa Cruz Biotechnology) primary antibody followed by PBST washes and horseradish peroxidase (1:10,000) secondary antibody application.
TUNEL assay. Sections were processed for terminal deoxynucleotidal transferase (TdT)-mediated dUTP-nick-end labeling (TUNEL) with the ApopTag Red InSitu Apoptosis Detection kit (Intergen) according to the manufacturer's instructions. Sections were counter- Statistics. In all studies, a one-way ANOVA was performed. If significance between the genotypes existed (P Յ 0.05), post hoc analysis by least significant difference (LSD) was performed to determine statistical significance (P Յ 0.05) between groups. All statistical analyses were performed using the Statview statistical program.
RESULTS
We crossed Cux1 tm1Ejn mice, which carry a 246 amino acid deletion in Cux1 that includes the first cut repeat (Cux1⌬CR1) (63) , with Cys1 cpk mice to generate mice homozygous for both genes (Cux1 tm1Ejn /Cys1 cpk ). Mice carrying the Cux1⌬CR1 mutation have curly whiskers, wavy hair, and lactation defects (63), but have normal kidneys (Fig. 1a) . Surprisingly, when this mutation was combined with the Cys1 cpk mutation, the double homozygous (Cux1 tm1Ejn /Cys1 cpk ) mice developed cystic kidneys that were significantly larger than the cystic kidneys from mice carrying only the Cys1 cpk mutation (Fig. 1) . Bilateral kidneys were harvested at postnatal day 10 (P10) and total KW and BW measurements were collected to calculate KW standardized as a percentage of BW, standard measurements to quantify renal cystic disease severity (24, 41) . By gross appearance, kidneys from Cux1 tm1Ejn /Cys1 cpk mice were significantly larger than kidneys from Cys1 cpk mice (Fig. 1b) . Cux1 tm1Ejn /Cys1 cpk kidneys were significantly larger compared with Cys1 cpk in regard to KW/BW, both at postnatal day 3 and 10 ( Fig. 1, c and d) . While Cys1 cpk mice heterozygote for the Cux1 tm1Ejn mutation showed a slight increase in KW/BW, it was not significant. Large cystic kidneys are directly correlated with reduced renal function and high BUN levels (13, 62 (Fig. 2, a and b) . Histological analysis showed that the overall number of renal cysts was not different between the Cys1 cpk and Cux1 tm1Ejn /Cys1 cpk mice (Fig. 2c) (3, 17) . Initially, Cys1 cpk mice develop proximal tubule cysts that resolve by postnatal day 7. This is followed by a second phase of cystogenesis, in which cysts develop primarily from collecting ducts, resulting in massive enlargement of the kidneys. In kidneys from both Cux1 tm1Ejn /Cys1 cpk and Cys1 cpk mice, the cysts were primarily restricted to the collecting ducts, with few proximal tubule cysts, although the collecting duct cysts in the Cux1⌬CR1/cpk kidneys were larger than those in the cpk kidneys (Fig. 2, e-h ). Our results suggest that the Cux1 tm1Ejn gene accelerates cyst growth, but does not induce cyst formation. Cell proliferation is a key feature of cyst growth (4, 8, 22, 68) . Moreover, there is a direct correlation between levels of cell proliferation and progression of cystic disease (8, 57, 62) . Thus, one possibility is that the increased cyst size observed in the kidneys from Cux1 tm1Ejn /Cys1 cpk mice resulted from increased proliferation of the cyst-lining epithelial cells. In the developing kidney, Cux1 is expressed in the nephrogenic zone where it colocalizes with markers for cell proliferation, but is downregulated in maturing glomeruli and tubules (64) . However, in Pkd1 null kidneys, Cux1 is ectopically expressed in the cyst-lining cells, and in normal appearing mature tubule epithelia, where it is associated with cell proliferation (53) . Wildtype Cux1 protein was not expressed in the cyst-lining cells of kidneys isolated from 10-day-old Cys1 cpk mice (Fig. 3, a-c) , as described previously (53) . In contrast, Cux1⌬CR1 protein colocalized with PCNA in the cyst-lining cells of kidneys isolated from 10-day-old Cux1 tm1Ejn /Cys1 cpk mice (Fig. 3, d-f ). While there is limited apoptosis in the cysts of 10-day-old Cys1 cpk mice, apoptosis is increased at later stages of cyst growth, where it is thought to contribute to cyst progression (8, 53) . Moreover, inhibition of apoptosis slows cyst progression in mouse and rat models of PKD (8, 57 (Fig. 3, g-i) .
The expanded expression of the Cux1⌬CR1 protein in the cystic kidneys was surprising since this deletion would not be expected to affect the regulatory elements in the Cux1 gene. Moreover, the levels of Cux1 tm1Ejn mRNA are not different from that of wild-type Cux1 (p200) mRNA (63) . However, the levels of Cux1⌬CR1 protein appear to be elevated in some tissues compared with Cux1 (p200). To determine whether the Cux1⌬CR1 protein was elevated in the kidney, we performed Western blot analysis on kidneys isolated from postnatal day 10 wild-type, Cys1 ). Figure 4 shows the expression of Cux1 (p200) in wild-type mice, which is completely processed to the p110 form in Cys1 cpk mice. This corresponded to an increase in nuclear cathepsin-L in Cys1 cpk mice, compared with wild-type mice. In contrast, the Cux1⌬CR1 protein is not processed in Cys1 cpk mice. Moreover, while p21 and p27 are both highly expressed in Cys1 cpk mice, they are downregulated in Cys1 cpk mice carrying one or two mutant Cux1 alleles (Fig. 4) . In addition, Cux1 is not expressed in the cyst-lining cells of Cys1 cpk mice (Fig. 5, a and j) , which is associated with the ectopic expression of p21 and p27 in the cyst-lining cells (Fig.  5, d, g, m, p) . In contrast, the Cux1⌬CR1 protein is ectopically expressed in the cyst-lining cells of Cux1 tm1Ejn /Cys1 cpk mice (Fig. 5, c and l) , and this is associated with reduced expression of p21 and p27 in the cyst-lining cells (Fig. 5, f, i, o, r) . Interestingly, Cys1 cpk mice heterozygote for the Cux1 tm1Ejn mutation (Cux1 tm1Ejn /ϩ/Cys1 cpk ) showed expression of the Cux1/Cux1⌬CR1 protein in cyst-lining cells (Fig. 5, b and k) that was associated with a reduction in p21 expression, but not p27 expression in the cyst-lining cells (Fig. 5, e, h, n, q) .
The Cux1 tm1Ejn phenotype is similar to previously described mouse mutants in the EGFR pathway, including wa-1 (35, 38) and wa-2 (16, 36) . The role of EGFR in PKD has been well-described (18, 29, 32, 49, 54) . Moreover, blocking EGFR activity, either genetically using the wa-2 mutation, or pharmacologically, results in decreased cyst formation and improved kidney function (49, 55, 56 Figure 5 shows that no differences in expression were found between Cys1 cpk and Cux1 tm1Ejn /Cys1 cpk mice (Fig. 5, s and t) . This is consistent with previous reports suggesting that the Cux1 tm1Ejn phenotype does not result from disruption of the EGFR pathway (63). tm1Ejn /Cys1 cpk (Cux1 tm1Ejn /Cux1 tm1Ejn :cpk/cpk) mice. The Cux1 (p200) protein is highly expressed in the WT kidney but is completely processed to the p110 form in Cys1 cpk kidneys. This is associated with an increase in both p21 and p27, and with an increase in nuclear cathepsin-L expression. The Cux1 tm1Ejn mutation generates a truncated protein (Cux1⌬CR1) that is not processed to the p110 form and is associated with the downregulation of p21 and p27. b: Relative densitometry of Cux1 (black bars), p27 (white bars), p21 (light gray bars), and cathepsin-L (dark gray bars) in nuclear extracts from 10-day-old WT, We previously reported differences in Cux1, p21, and p27 expression in mice with ARPKD (Cys1 cpk ) and ADPKD (Pkd1 null) (53) . To determine whether these expression differences might result from differences in the proteolytic processing of Cux1, we evaluated Cux1 expression in epithelial cells isolated from cysts of human ADPKD kidneys or tubules of NHKs. We were unable to detect full-length Cux1 (p200) protein in nuclear extracts from NHK (Fig. 6a) . However, there was an accumulation of full-length Cux1 (p200) protein in the nuclear extracts of cells isolated from the cysts of ADPKD kidneys (Fig. 6a) . To determine whether this increase in full-length Cux1 (p200) protein was from decreased proteolytic processing, we compared nuclear cathepsin-L levels in NHK and ADPKD cells. Figure 6b shows that nuclear cathepsin-L was significantly reduced in ADPKD cells. When we examined cathepsin-L expression in kidneys isolated from embryonic wild-type and Pkd1 null mice, we found that nuclear cathepsin-L was similarly reduced in Pkd1 null mice (Fig. 6, c and d) .
DISCUSSION
Cux1 is highly expressed in the nephrogenic zone during normal kidney development where it functions to repress p27 gene expression promoting cell proliferation (30, 64) . Transgenic mice expressing the Cux1 (p200) cDNA using the CMV immediate early gene promoter develop multiorgan hyperplasia and exhibit continued cell proliferation in adult kidneys (30) . However, these mice do not develop renal cysts, suggesting that cell proliferation alone is insufficient for cystogenesis.
Cux1 tm1Ejn mice carry an in-frame deletion of Cux1, encompassing exons 15 and 16 (60) . The Cux1 tm1Ejn phenotype is similar to previously described mouse mutants in the EGFR pathway (16, 35, 36, 38) . The role of EGFR in PKD has been well-described (18, 29, 32, 49, 54) . Moreover, blocking EGFR activity, either genetically or pharmacologically, results in decreased cyst formation and improved kidney function (49, 55, 56 Cux1 (p200) represses p21 and p27 promoter activity in a concentration-dependent manner (10, 25 cpk phenotype. This is consistent with previous studies showing that p21 null mice do not exhibit a cell proliferation defect (14) , while p27 knockout mice develop hyperplasia (15, 28, 42 During S-phase of the cell cycle, a nuclear isoform of cathepsin-L proteolytically processes the Cux1 (p200) at amino acids 643, 747, and 755 to generate the p110 isoform (21) . The deletion in the Cux1⌬CR1 protein includes the first cut repeat and the cathepsin-L site at position 643, while the cathepsin-L sites a positions 747 and 755 remain in the mutant protein. While Cux1 (p200) is completely processed to the p110 isoform in kidneys from Cys1 cpk mice, the Cux1⌬CR1 protein is not processed in kidneys from Cux1 tm1Ejn /Cys1 cpk mice, suggesting the mutant Cux1⌬CR1 protein is more stable than the wild-type protein.
In contrast to Cys1 cpk mice, nuclear cathepsin-L is reduced in both human ADPKD cells and in Pkd1 null kidneys. This suggests a mechanism in which reduced processing results in the accumulation of Cux1 (p200) leading to downregulation of p21 and p27 and increased cell proliferation in ADPKD. In contrast, the levels of nuclear cathepsin-L were not reduced in kidneys from Cys1 cpk mice compared with kidneys from wildtype mice. Thus, in Cys1 cpk mice, Cux1 (p200) would not escape proteolytic processing, and therefore would not accumulate. However, deletion of the first cathepsin-L cleavage site in Cux1⌬CR1 reduces proteolytic processing resulting in Cux1⌬CR1 protein accumulation.
It is of interest that reduced activity of cathepsin-L has previously been reported in the Han:SPRD rat model of PKD (52) and in human ADPKD cells (25) . In both, the reduced activity was not a result of decreased gene expression, but of abnormal targeting of the enzyme. It is similarly possible that reduction of the nuclear isoform of cathepsin-L in human ADPKD cells and in kidneys from Pkd1 null mice is the result of abnormal targeting.
